rss
Br J Ophthalmol 2003;87:753-757 doi:10.1136/bjo.87.6.753
  • Original Article
    • Clinical science

The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration

  1. A Harris1,
  2. T A Ciulla2,
  3. L M Pratt1,
  4. E Rechtman1,
  5. L Kagemann1,
  6. H C Piper1,
  7. H J Garzozi3
  1. 1Department of Ophthalmology, Indiana University School of Medicine, IN, USA
  2. 2Midwest-Eye Institute, Indianapolis, IN, USA
  3. 3Department of Ophthalmology, Bnai Zion Medical Center, Haifa, Israel
  1. Correspondence to: Alon Harris, PhD, 702 Rotary Circle, IUMC, Indianapolis, IN 46260, USA; alharris{at}indiana.edu
  • Accepted 1 October 2002

Abstract

Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD).

Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months.

Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19).

Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
     This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.